Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Eytan M. Stein, Abigail Shoben, Uma Borate, Maria R. Baer, Wendy Stock, Prapti A. Patel, Tibor Kovacsovics, William Blum, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Sonja Marcus, Mona Stefanos, Jordan Chervin, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Alice S. Mims
Institutions: Memorial Sloan Kettering Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Oregon Health & Science University, OHSU Knight Cancer Institute, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Chicago, The University of Texas Southwestern Medical Center, University of Utah, Huntsman Cancer Institute, Winship Cancer Institute, Foundation Medicine (United States), Blood Cancer United, The Ohio State University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2901370692